The Berlin Capsulution NanoScience AG completed the first half of 2006 by doubling the previous year’s turnover in the same period, while at the same time Capsulution’s EBIT increased to more than TEUR 200. Capsulution was able to enter a positive overall result in the ledger and is looking forward to an auspicious future. By the end of 2006 sales revenues of well over 1 million EUR are expected.
Alexander Hermann, chief financial officer, states: “We are pleased to have surpassed the goals we aspired to, for this generates a high degree of confidence in the company’s growth forecasts among all involved: customers, staff and investors. In the coming months the result will be impaired by high advance costs in the R & D area, especially due to scheduled pre-clinical experiments. However, the successful conclusion of these tests promises a considerable increase in turnover in the next fiscal year, as a large number of potential pharmaceutical customers hold them to be an important milestone for expanding and intensifying business relations with Capsulution.”
Alexander Hermann, chief financial officer, states: “We are pleased to have surpassed the goals we aspired to, for this generates a high degree of confidence in the company’s growth forecasts among all involved: customers, staff and investors. In the coming months the result will be impaired by high advance costs in the R & D area, especially due to scheduled pre-clinical experiments. However, the successful conclusion of these tests promises a considerable increase in turnover in the next fiscal year, as a large number of potential pharmaceutical customers hold them to be an important milestone for expanding and intensifying business relations with Capsulution.”
